Cargando…

Current State of the First COVID-19 Vaccines

SARS CoV-2 and its associated disease COVID-19 has devastated the world during 2020. Masks and social distancing could be efficient if done by large proportions of the population, but pandemic fatigue has decreased their efficacy. Economic shut downs come with large price tags and cannot be a long t...

Descripción completa

Detalles Bibliográficos
Autor principal: Prüβ, Birgit M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826947/
https://www.ncbi.nlm.nih.gov/pubmed/33429880
http://dx.doi.org/10.3390/vaccines9010030
_version_ 1783640642386132992
author Prüβ, Birgit M.
author_facet Prüβ, Birgit M.
author_sort Prüβ, Birgit M.
collection PubMed
description SARS CoV-2 and its associated disease COVID-19 has devastated the world during 2020. Masks and social distancing could be efficient if done by large proportions of the population, but pandemic fatigue has decreased their efficacy. Economic shut downs come with large price tags and cannot be a long term solution either. The announcements by three vaccine manufacturers in November that their vaccines are 90% or more effective has given hope to at least those in the population who plan to get vaccinated as soon as a scientifically and medically sound vaccine becomes available. This review summarizes the underlying design strategies and current status of development of the nine vaccines that were in phase III trial on 8 November 2020. Contracts between vaccine manufacturing companies and governments aim at distributing the vaccine to a large part of the world population. Questions remain how the temperature sensitive mRNA vaccines will be transported and/or stored and how vaccination will be prioritized within each country. Additionally, current contracts do not cover all countries, with a serious gap in Africa and South America. The second part of this review will detail current distribution plans and remaining challenges with vaccine accessibility and acceptance.
format Online
Article
Text
id pubmed-7826947
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78269472021-01-25 Current State of the First COVID-19 Vaccines Prüβ, Birgit M. Vaccines (Basel) Review SARS CoV-2 and its associated disease COVID-19 has devastated the world during 2020. Masks and social distancing could be efficient if done by large proportions of the population, but pandemic fatigue has decreased their efficacy. Economic shut downs come with large price tags and cannot be a long term solution either. The announcements by three vaccine manufacturers in November that their vaccines are 90% or more effective has given hope to at least those in the population who plan to get vaccinated as soon as a scientifically and medically sound vaccine becomes available. This review summarizes the underlying design strategies and current status of development of the nine vaccines that were in phase III trial on 8 November 2020. Contracts between vaccine manufacturing companies and governments aim at distributing the vaccine to a large part of the world population. Questions remain how the temperature sensitive mRNA vaccines will be transported and/or stored and how vaccination will be prioritized within each country. Additionally, current contracts do not cover all countries, with a serious gap in Africa and South America. The second part of this review will detail current distribution plans and remaining challenges with vaccine accessibility and acceptance. MDPI 2021-01-08 /pmc/articles/PMC7826947/ /pubmed/33429880 http://dx.doi.org/10.3390/vaccines9010030 Text en © 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Prüβ, Birgit M.
Current State of the First COVID-19 Vaccines
title Current State of the First COVID-19 Vaccines
title_full Current State of the First COVID-19 Vaccines
title_fullStr Current State of the First COVID-19 Vaccines
title_full_unstemmed Current State of the First COVID-19 Vaccines
title_short Current State of the First COVID-19 Vaccines
title_sort current state of the first covid-19 vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826947/
https://www.ncbi.nlm.nih.gov/pubmed/33429880
http://dx.doi.org/10.3390/vaccines9010030
work_keys_str_mv AT prubbirgitm currentstateofthefirstcovid19vaccines